Skip to main content

Advertisement

SpringerLink
Log in

The Role of Urodynamic Testing Prior to Third-Line OAB Therapy

  • Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review outlines current guidelines and evidence for the use of urodynamic testing prior to the initiation of third-line overactive bladder (OAB) treatment options.

Recent Findings

OAB currently affects many patients with a significant impact on quality of life as well as health care resources. Treatment algorithms proceed from least to most invasive in an attempt to ameliorate symptoms, namely, urgency, frequency, and urgency incontinence. The current third-line OAB management strategies include percutaneous tibial nerve stimulation (PTNS), sacral nerve stimulation (SNS), and onabotulinumtoxinA injection. These modalities are reserved for patients that have gained insufficient symptom control or are intolerant of less invasive treatments.

Urodynamic studies (UDS) are typically performed to help guide treatment planning and/or to evaluate for harmful urologic conditions. Currently available studies do not show a clear link between UDS results and treatment OAB success. The finding of detrusor overactivity (DO) has not been clearly established as a prerequisite to have clinical benefit with third-line OAB treatments in the uncomplicated idiopathic OAB patient population. There is some evidence that patients with DO on UDS may benefit more; however, additional blinded placebo-controlled studies are needed.

Summary

Urodynamics should be used judiciously for patients with known or suspected voiding phase dysfunction, those with rapidly changing symptoms, those in whom the diagnosis is not clear, those who have medical or urological histories that can affect outcomes of treatment, and in those with known or suspected neurological disease. Although urodynamics may influence clinical decision-making, our review does not support the role of these investigations as predictors of outcomes in patients with uncomplicated, idiopathic overactive bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.

    Article  PubMed  Google Scholar 

  2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306–14.

    Article  PubMed  Google Scholar 

  3. •• Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63 Current AUA guideline on OAB management.

    Article  PubMed  Google Scholar 

  4. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572–80.

    Article  PubMed  Google Scholar 

  5. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019 Sep;202(3):558–63.

    Article  PubMed  Google Scholar 

  6. •• Urinary Incontinence Guideline. European Association of Urology. http://www.uroweb.org/guideline/urinary-incontinence. Accessed 14 May 2020. Current EAU guideline on urinary incontinence including OAB management.

  7. •• Urinary incontinence and pelvic organ prolapse in women pathway. National Institute for Health and Care Excellence. https://pathways.nice.org.uk/pathways/urinary-incontinence-and-pelvic-organ-prolapse-in-women. Accessed 14 May 2020. Current NICE guideline on UI and POP, including advancing to third-line OAB treatment.

  8. Sussman RD, Syan R, Brucker BM. Guideline of guidelines: urinary incontinence in women. BJU Int. 2020 May;125(5):638–55.

    Article  PubMed  Google Scholar 

  9. Kirby AC, Park S, Cook SB, Odem-Davis K, Gore JL, Wolff EM. Practice patterns for women with overactive bladder syndrome: time between medications and third-line treatments. Female Pelvic Med Reconstr Surg. 2020. https://doi.org/10.1097/SPV.0000000000000811.

  10. Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, et al. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int. 2012;89:1–8.

    Article  CAS  PubMed  Google Scholar 

  11. International Continence Society Terminology Discussion: overactive bladder. https://www.ics.org/committees/standardisation/terminologydiscussions/overactivebladder. Accessed 14 May 2020.

  12. Al Mousa RT, Al Dossary N, Hashim H. The role of urodynamics in females with lower urinary tract symptoms. Arab J Urol. 2019;17(1):2–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11(3):117–25.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lin FC, Nitti VW. Voiding dysfunction in women. In: Walters MD, Karram MM, editors. Urogynecology and reconstructive pelvic surgery. 5th ed. Philadelphia: Elsevier Saunders; 2020. In Press.

    Google Scholar 

  15. Overactive Bladder Clinical Care Pathway. Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Foundation. https://sufuorg.com/resources/overactive-bladder-ccp.aspx. Accessed 14 May 2020.

  16. • Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199(3):779–84 This study demonstrated the low utilization of third-line OAB treatment options.

    Article  PubMed  Google Scholar 

  17. Rohloff M, Peifer G, Thompson JH. Patient navigation for overactive bladder improves access to care. Int Urogynecol J. 2020;31(5):1007–12.

    Article  PubMed  Google Scholar 

  18. Glass D, Lin FC, Khan AA, Van Kuiken M, Drain A, Siev M, et al. Impact of preoperative urodynamics on women undergoing pelvic organ prolapse surgery. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04084-8.

  19. NICE guideline [NG123]: Statement 1.4.43. Invasive procedures for overactive bladder. Urinary incontinence and pelvic organ prolapse in women: management. Published date: 02 April 2019. https://www.nice.org.uk/guidance/ng123/chapter/Recommendations. Accessed 14 May 2020.

  20. Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010;105(9):1268–75.

    Article  CAS  PubMed  Google Scholar 

  21. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int. 2003;92(4):415–7.

    Article  CAS  PubMed  Google Scholar 

  22. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int. 2009;103(7):931–7.

    Article  PubMed  Google Scholar 

  23. • Kopp Kallner H, Elmér C, Altman D. Urodynamics as a prognosticator of mirabegron treatment outcomes. Gynecol Obstet Invest. 2019;84(5):472–6 This study evaluated predictors of beta-3 agonist therapy success.

    Article  PubMed  Google Scholar 

  24. Vandoninck V, van Balken MR, Finazzi Agrò E, Petta F, Micali F, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 2003;22(3):227–32.

    Article  PubMed  Google Scholar 

  25. Del Río-Gonzalez S, Aragon IM, Castillo E, Milla-España F, Galacho A, Machuca J, et al. Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durability evaluation. Urology. 2017;108:52–8.

    Article  PubMed  Google Scholar 

  26. Rostaminia G, Chang C, Pincus JB, Sand PK, Goldberg RP. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. 2019;30(10):1735–45.

    Article  PubMed  Google Scholar 

  27. Nobrega RP, Solomon E, Jenks J, Greenwell T, Ockrim J. Predicting a successful outcome in sacral neuromodulation testing: are urodynamic parameters prognostic? Neurourol Urodyn. 2018;37(3):1007–10.

    Article  PubMed  Google Scholar 

  28. South MM, Romero AA, Jamison MG, Webster GD, Amundsen CL. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(12):1395–8.

    Article  PubMed  Google Scholar 

  29. Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB, et al. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 2008;101(3):325–9.

    Article  PubMed  Google Scholar 

  30. Cui Y, Zhou X, Zong H, Yan H, Zhang Y. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn. 2015;34(5):413–9.

    Article  CAS  PubMed  Google Scholar 

  31. Przydacz M, Golabek T, Chlosta P. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA. Adv Clin Exp Med. 2019;28(4):555–67.

    Article  PubMed  Google Scholar 

  32. Cohen BL, Caruso DJ, Kanagarajah P, Gousse AE. Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol. 2009:328364. https://doi.org/10.1155/2009/328364.

  33. • Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22 This study was a dose finding trial to evaluate onabotulinumtoxinA use in OAB.

    Article  CAS  PubMed  Google Scholar 

  34. • Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93 This study demonstrated clinical benefit of onabotulinumtoxinA 100 units in OAB patients.

    Article  CAS  PubMed  Google Scholar 

  35. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.

    Article  CAS  PubMed  Google Scholar 

  36. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62.

    Article  CAS  PubMed  Google Scholar 

  37. Jackson BL, Burge F, Bronjewski E, Parkinson RJ. Intravesical botulinum toxin for overactive bladder syndrome without detrusor overactivity. Br J Med Surg Urol. 2012;5:169–73.

    Article  Google Scholar 

  38. •• Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review. Int Urogynecol J. 2017;28(6):805–16 Meta-analysis of third-line OAB treatment success in the presence and absence of detrusor overactivity on UDS.

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received.

Author information

Authors and Affiliations

  1. Department of Urology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Frank C. Lin

  2. Department of Urology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Victor W. Nitti

Authors
  1. Frank C. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor W. Nitti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank C. Lin.

Ethics declarations

Conflict of Interest

Frank Lin, MD, declares that he has no conflict of interest. Victor Nitti, MD, is an investigator for Allergan, Astellas Pharma, and Medtronic.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Voiding Dysfunction Evaluation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, F.C., Nitti, V.W. The Role of Urodynamic Testing Prior to Third-Line OAB Therapy. Curr Bladder Dysfunct Rep 15, 159–165 (2020). https://doi.org/10.1007/s11884-020-00587-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-020-00587-z

Keywords

Search

Navigation